Bevacizumab
Contents
Description
Bevacizumab is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A). While primarily approved for various cancers, it is widely used off-label for neovascular age-related macular degeneration and other retinal diseases. The drug prevents angiogenesis and vascular permeability in the retina.
Indications & Therapeutic Use
metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, off-label: neovascular age-related macular degeneration
Global Availability (12 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Bevacizumab — GNH India
64 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
| Generic Name | bevacizumab |
| Brands | 1 brand available |
| Active Ingredient | bevacizumab |
| Drug Class | metastatic colorectal cancer |
| Manufacturer | Genentech/Roche |
| Dosage Forms | IV infusion, 25 mg/mL solution; intravitreal injection (off-label) |
| Medical Code | L01XC07 |
| Orphan Status | No |
| Cold Chain | Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved, EMA Approved |
| Clinical Trial | NCT00321594 |
| Countries | 12 countries |